Thomas Cueni takes over as IFPMA director general

7 February 2017

Thomas Cueni has taken up office as director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) on February 1, representing the interests of the research-based biopharmaceutical industry at a global level.

He succeeds Eduardo Pisani, who served as the organization’s DG for seven years and announced his decision to leave in November 2016, saying it was “time to move on to a new challenge.”

Thomas Cueni is highly respected across the biopharmaceutical sector, having served for many years as secretary general of Interpharma, the association of pharmaceutical research companies in Switzerland. He has been closely associated with the IFPMA throughout his tenure at Interpharma as a member of the Council of the IFPMA. He has also been instrumental in shaping policy and advocating with European Institutions on behalf of the EFPIA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK